218 related articles for article (PubMed ID: 7707373)
1. The crystal structure of cruzain: a therapeutic target for Chagas' disease.
McGrath ME; Eakin AE; Engel JC; McKerrow JH; Craik CS; Fletterick RJ
J Mol Biol; 1995 Mar; 247(2):251-9. PubMed ID: 7707373
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi.
Chen YT; Brinen LS; Kerr ID; Hansell E; Doyle PS; McKerrow JH; Roush WR
PLoS Negl Trop Dis; 2010 Sep; 4(9):. PubMed ID: 20856868
[TBL] [Abstract][Full Text] [Related]
3. Cysteine protease isoforms from Trypanosoma cruzi, cruzipain 2 and cruzain, present different substrate preference and susceptibility to inhibitors.
Lima AP; dos Reis FC; Serveau C; Lalmanach G; Juliano L; Ménard R; Vernet T; Thomas DY; Storer AC; Scharfstein J
Mol Biochem Parasitol; 2001 Apr; 114(1):41-52. PubMed ID: 11356512
[TBL] [Abstract][Full Text] [Related]
4. Cruzain : the path from target validation to the clinic.
Sajid M; Robertson SA; Brinen LS; McKerrow JH
Adv Exp Med Biol; 2011; 712():100-15. PubMed ID: 21660661
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of the parasite inhibitor chagasin in complex with papain allows identification of structural requirements for broad reactivity and specificity determinants for target proteases.
Redzynia I; Ljunggren A; Bujacz A; Abrahamson M; Jaskolski M; Bujacz G
FEBS J; 2009 Feb; 276(3):793-806. PubMed ID: 19143838
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design, synthesis and evaluation of conformationally constrained cysteine protease inhibitors.
Scheidt KA; Roush WR; McKerrow JH; Selzer PM; Hansell E; Rosenthal PJ
Bioorg Med Chem; 1998 Dec; 6(12):2477-94. PubMed ID: 9925304
[TBL] [Abstract][Full Text] [Related]
7. Identification of a new class of nonpeptidic inhibitors of cruzain.
Brak K; Doyle PS; McKerrow JH; Ellman JA
J Am Chem Soc; 2008 May; 130(20):6404-10. PubMed ID: 18435536
[TBL] [Abstract][Full Text] [Related]
8. Crystal structures of reversible ketone-Based inhibitors of the cysteine protease cruzain.
Huang L; Brinen LS; Ellman JA
Bioorg Med Chem; 2003 Jan; 11(1):21-9. PubMed ID: 12467703
[TBL] [Abstract][Full Text] [Related]
9. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
[TBL] [Abstract][Full Text] [Related]
10. Cysteine protease inhibitors alter Golgi complex ultrastructure and function in Trypanosoma cruzi.
Engel JC; Doyle PS; Palmer J; Hsieh I; Bainton DF; McKerrow JH
J Cell Sci; 1998 Mar; 111 ( Pt 5)():597-606. PubMed ID: 9454733
[TBL] [Abstract][Full Text] [Related]
11. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection.
Doyle PS; Zhou YM; Engel JC; McKerrow JH
Antimicrob Agents Chemother; 2007 Nov; 51(11):3932-9. PubMed ID: 17698625
[TBL] [Abstract][Full Text] [Related]
12. Production of crystallizable cruzain, the major cysteine protease from Trypanosoma cruzi.
Eakin AE; McGrath ME; McKerrow JH; Fletterick RJ; Craik CS
J Biol Chem; 1993 Mar; 268(9):6115-8. PubMed ID: 8454586
[TBL] [Abstract][Full Text] [Related]
13. A target within the target: probing cruzain's P1' site to define structural determinants for the Chagas' disease protease.
Brinen LS; Hansell E; Cheng J; Roush WR; McKerrow JH; Fletterick RJ
Structure; 2000 Aug; 8(8):831-40. PubMed ID: 10997902
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of the parasite protease inhibitor chagasin in complex with a host target cysteine protease.
Ljunggren A; Redzynia I; Alvarez-Fernandez M; Abrahamson M; Mort JS; Krupa JC; Jaskolski M; Bujacz G
J Mol Biol; 2007 Aug; 371(1):137-53. PubMed ID: 17561110
[TBL] [Abstract][Full Text] [Related]
15. The Trypanosoma cruzi protease cruzain mediates immune evasion.
Doyle PS; Zhou YM; Hsieh I; Greenbaum DC; McKerrow JH; Engel JC
PLoS Pathog; 2011 Sep; 7(9):e1002139. PubMed ID: 21909255
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of chagasin, the endogenous cysteine-protease inhibitor from Trypanosoma cruzi.
Figueiredo da Silva AA; de Carvalho Vieira L; Krieger MA; Goldenberg S; Zanchin NI; Guimarães BG
J Struct Biol; 2007 Feb; 157(2):416-23. PubMed ID: 17011790
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of potent azadipeptide nitrile inhibitors and activity-based probes as promising anti-Trypanosoma brucei agents.
Yang PY; Wang M; Li L; Wu H; He CY; Yao SQ
Chemistry; 2012 May; 18(21):6528-41. PubMed ID: 22488888
[TBL] [Abstract][Full Text] [Related]
18. Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy.
Brak K; Kerr ID; Barrett KT; Fuchi N; Debnath M; Ang K; Engel JC; McKerrow JH; Doyle PS; Brinen LS; Ellman JA
J Med Chem; 2010 Feb; 53(4):1763-73. PubMed ID: 20088534
[TBL] [Abstract][Full Text] [Related]
19. Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for Chagas' disease.
Neitz RJ; Bryant C; Chen S; Gut J; Hugo Caselli E; Ponce S; Chowdhury S; Xu H; Arkin MR; Ellman JA; Renslo AR
Bioorg Med Chem Lett; 2015 Nov; 25(21):4834-4837. PubMed ID: 26144347
[TBL] [Abstract][Full Text] [Related]
20. Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi.
Harth G; Andrews N; Mills AA; Engel JC; Smith R; McKerrow JH
Mol Biochem Parasitol; 1993 Mar; 58(1):17-24. PubMed ID: 8459830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
